Clinical trials: Ebola Hemorrhagic Fever
Ebola Virus Disease
Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines
The aim of this study is to investigate the persistence of the vaccine induced immune response between 24 - 60 months following primary vaccination.
- Trial name
- PRISM (NCT03140774)
- Testing
- Previously exposed to Ebola vaccine
- Where
- 2 sites in United Kingdom
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Ebola Hemorrhagic Fever
Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6002, a post-exposure prophylaxis candidate treatment for Ebolavirus.
- Trial name
- NCT01353027
- Testing
- AVI-6002
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Ebola Virus Disease, Marburg Virus Disease
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
Primary Objective: To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults.
- Trial name
- NCT04723602
- Testing
- cAd3-Marburg, cAd3-EBO-S
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Immune Response
Surveillance of Vaccine-induced Immunity Against Ebola in Previously Vaccinated Health Care Workers
During the previous Ebola virus disease (EVD) outbreaks, the institute National de Recherche Biomédicale (INRB) and other institutional's staff in Democratic Republic of the Congo (DRC) got vaccinated with the rVSV-ZEBOV vaccine.
- Trial name
- EBOSURV (NCT05313139)
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Healthy
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
The purpose of this study is to compare the humoral immune response induced by 3 different batches of Ad26.ZEBOV as measured by enzyme - linked immunosorbent assay (ELISA) against the Ebola virus (EBOV) GP (Glycoprotein) at 56…
- Trial name
- NCT02543268
- Testing
- Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3
- Where
- 6 sites in United States
- Volunteers
- 329 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Ebola Virus Disease
Partnership for Research on Ebola VACcinations
The purpose of this study is to evaluate the safety and immunogenicity of three vaccine strategies that may prevent Ebola virus disease (EVD) events in children and adults.
- Trial name
- PREVAC (NCT02876328)
- Testing
- Ad26.ZEBOV, MVA-BN-Filo, rVSVΔG-ZEBOV-GP
- Where
- 6 sites in Guinea, Liberia and 2 more
- Volunteers
- 4,789 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
REVIVE (Response to the Ebola Virus Vaccine)
This study is a vaccine-related clinical trial which will be conducted by our study team at Kenema Government Hospital (KGH)'s Viral Hemorrhagic Fever Program in collaboration with Tulane University School of Medicine.
- Trial name
- NCT05992480
- Testing
- rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)
- Where
- Sierra Leone
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tulane University
Ebola Hemorrhagic Fever, Lassa Hemorrhagic Fever
Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - GUINEA
This study aim to validate the clinical performances of two newly developed isothermal nucleic acid amplification bioassays modules for EBOV and LASV.
- Trial name
- NCT07681752
- Testing
- FORTIFIEDx and DECIPHER bioassays
- Volunteers
- 150 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Ebola Virus Disease
Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Virus Disease
This study highlighted the possibility, even in epidemic settings, of providing advanced supportive care for patients with VMEs.
- Trial name
- EVISTA (NCT04815174)
- Testing
- Standard of Care
- Where
- Democratic Republic of the Congo
- Volunteers
- 711 people
- Sponsor
- Alliance for International Medical Action
Ebola Virus Disease, Prevention
International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi
The purpose of this study is to evaluate immunogenicity, epidemiological efficacy and safety of medicinal product GamEvac-Combi - Combined Vector-Based Vaccine against Ebola Virus Disease, 0.5 ml+0.5 ml/dose
- Trial name
- NCT03072030
- Testing
- GamEvac-Combi (vaccine)
- Where
- 2 sites in Guinea, Russia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Ebola Virus Disease
Prophylaxis Vaccine Antibodies Ebola
Three measures are currently being implemented to control Ebola outbreaks: Monitoring of contacts Isolation and treatment of sick people Vaccination of the population in high-risk areas.
- Trial name
- PROVAE (NCT04822376)
- Testing
- ansuvimab, Ervebo
- Where
- Guinea
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Ebola Hemorrhagic Fever
Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - DRC
This study aims to validate the clinical performance of a newly developed isothermal nucleic acid amplification bioassay module for EBOV.
- Trial name
- NCT07688083
- Testing
- DECIPHER bioassay
- Volunteers
- 100 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Virus Diseases
A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children
The purpose of this study is to assess the safety and reactogenicity of a single IM dose of the GSK3390107A (ChAd3 EBO-Z) vaccine, overall and in children aged 1 to 5, 6 to 12, and 13 to 17 years, separately.
- Trial name
- NCT02548078
- Testing
- GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A), Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine
- Where
- 2 sites in Mali, Senegal
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ebola Virus Survivor
Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen
This study aims to evaluate favipiravir high dose tolerance in male survivor of Ebola Virus Disease (EVD) with Ebola Virus (EBOV) RNA in semen.
- Trial name
- FORCE (NCT02739477)
- Testing
- Favipiravir
- Where
- 2 sites in Guinea
- Volunteers
- 2 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Ebola Disease, Marburg Disease
A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers
This is a Phase 1, double-blind, randomized trial to evaluate the safety and immunogenicity of two heterologous and two homologous prime-boost regimens using MVA-BN(R)-Filo and Ad26.ZEBOV administered in different sequences at…
- Trial name
- NCT02891980
- Testing
- Ad26 Zaire Ebola Vaccine, MVA Multi-Filo Ebola Vaccine
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prevention of Ebola Infection
Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)
The study evaluated the safety and immunogenicity of 3 consistency lots and a high-dose lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in healthy adults.
- Trial name
- NCT02503202
- Testing
- V920 Consistency Lot A, V920 Consistency Lot B, V920 Consistency Lot C
- Volunteers
- 1,197 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Ebola Virus Disease
Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola)
Ebola virus is one of the most dangerous human pathogens and is an emerging public health problem in sub-Saharan Africa. Ebola virus disease (EVD) first appeared in 1976.
- Trial name
- NCT04409405
- Where
- 4 sites in Democratic Republic of the Congo
- Volunteers
- 787 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Ebola Virus Disease
Evaluation of the FilmArray BioThreat-E Test
The aim of our study is to assess the analytical and clinical performance of the FilmArray (FA) BioThreat-E test (BioFire®) for the diagnosis of Ebola virus disease in the field in Guinea versus conventional molecular techniques.
- Trial name
- NCT02658331
- Volunteers
- 156 people
- Sponsor
- BioMérieux
Ebola Sudan Virus Disease
Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults
- Trial name
- NCT06036602
- Testing
- cAD3-Sudan Ebolavirus Vaccine
- Where
- 2 sites in Kenya, Uganda
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Hemorrhagic Fever, Ebola
Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)
The study is designed to establish safety, tolerability and immunogenicity of rVSVΔG-ZEBOV-GP (BPSC1001), an Ebola Virus Vaccine candidate (recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoprotein of…
- Trial name
- NCT02283099
- Testing
- rVSVΔ-ZEBOV-GP
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf